BRIEF—Poseida raises $142 million

Poseida Therapeutics has raised $142 million in a series C round, led by a $75 million equity investment from Novartis Pharma.

Darragh Lyons, chief business officer of major investor Malin Corporation said: "Novartis' significant participation serves as additional validation of Poseida's high-quality and differentiated pipeline and technology platforms with broad utility.”

"Poseida has significantly strengthened its balance sheet position and expanded its institutional investor base as the company moves into an important phase of clinical development, including initiating a registrational study for its lead product candidate and the advancement of three further programmes into the clinic."